{"title":"尿路致病性大肠埃希菌的抗菌药耐药性和 ESBL 生产:埃塞俄比亚的系统回顾和荟萃分析。","authors":"Zelalem Asmare, Mulat Erkihun, Wagaw Abebe, Ephrem Tamrat","doi":"10.1093/jacamr/dlae068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) is a serious threat to global health systems. <i>Escherichia coli</i> is a major cause of urinary tract infections (UTIs). Understanding the AMR patterns of uropathogenic <i>E. coli</i> (UPEC) is crucial for effective public health interventions worldwide.</p><p><strong>Objectives: </strong>This systematic review and meta-analysis aimed to consolidate existing research and provide a comprehensive information on AMR UPEC in Ethiopia.</p><p><strong>Methods: </strong>We systematically searched databases such as PubMed, Web of Science, and Science Direct, along with including articles from Google Scholar. Data were extracted into Microsoft Excel and analysed using STATA 17.0. Cohen's kappa was computed to assess reviewer agreement, while the I<sup>2</sup> statistic evaluated heterogeneity. Egger's tests were conducted to detect publication bias, and random-effects models were utilized to estimate the pooled resistance, with AMR rates for each antibiotic pooled separately.</p><p><strong>Results: </strong>UPEC showed resistance rates, ranging from 3.64% (95% CI: -4.38% to 11.67%) for amikacin to 85.32% (95% CI: 78.6%-92.04%) for ampicillin. Highest resistance was to ampicillin (85.32%), followed by amoxicillin at 82.52% (95% CI: 74.3%-90.74%), tetracycline at 60.67% (95% CI: 51.53%-69.81%) and trimethoprim/sulfamethoxazole at 57.17% (95% CI: 49.93%-64.42%). Conversely, resistance rates were lower for amikacin at 3.64% and meropenem at 5.26% (95% CI: 2.64%-7.88%). UPEC demonstrated a pooled MDR rate of 79.17% (95% CI: 70.32%-88.01%) and a pooled ESBL production rate of 29.16% (95% CI: 22.36%-38.55%).</p><p><strong>Conclusions: </strong>High levels of AMR were observed in UPEC strains, highlighting a critical public health issue requiring urgent action through robust antimicrobial stewardship and surveillance to preserve effective UTI treatment options.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073753/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antimicrobial resistance and ESBL production in uropathogenic <i>Escherichia coli</i>: a systematic review and meta-analysis in Ethiopia.\",\"authors\":\"Zelalem Asmare, Mulat Erkihun, Wagaw Abebe, Ephrem Tamrat\",\"doi\":\"10.1093/jacamr/dlae068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antimicrobial resistance (AMR) is a serious threat to global health systems. <i>Escherichia coli</i> is a major cause of urinary tract infections (UTIs). Understanding the AMR patterns of uropathogenic <i>E. coli</i> (UPEC) is crucial for effective public health interventions worldwide.</p><p><strong>Objectives: </strong>This systematic review and meta-analysis aimed to consolidate existing research and provide a comprehensive information on AMR UPEC in Ethiopia.</p><p><strong>Methods: </strong>We systematically searched databases such as PubMed, Web of Science, and Science Direct, along with including articles from Google Scholar. Data were extracted into Microsoft Excel and analysed using STATA 17.0. Cohen's kappa was computed to assess reviewer agreement, while the I<sup>2</sup> statistic evaluated heterogeneity. Egger's tests were conducted to detect publication bias, and random-effects models were utilized to estimate the pooled resistance, with AMR rates for each antibiotic pooled separately.</p><p><strong>Results: </strong>UPEC showed resistance rates, ranging from 3.64% (95% CI: -4.38% to 11.67%) for amikacin to 85.32% (95% CI: 78.6%-92.04%) for ampicillin. Highest resistance was to ampicillin (85.32%), followed by amoxicillin at 82.52% (95% CI: 74.3%-90.74%), tetracycline at 60.67% (95% CI: 51.53%-69.81%) and trimethoprim/sulfamethoxazole at 57.17% (95% CI: 49.93%-64.42%). Conversely, resistance rates were lower for amikacin at 3.64% and meropenem at 5.26% (95% CI: 2.64%-7.88%). UPEC demonstrated a pooled MDR rate of 79.17% (95% CI: 70.32%-88.01%) and a pooled ESBL production rate of 29.16% (95% CI: 22.36%-38.55%).</p><p><strong>Conclusions: </strong>High levels of AMR were observed in UPEC strains, highlighting a critical public health issue requiring urgent action through robust antimicrobial stewardship and surveillance to preserve effective UTI treatment options.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073753/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlae068\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:抗菌药耐药性(AMR)是对全球卫生系统的严重威胁。大肠杆菌是尿路感染(UTI)的主要病因。了解尿路致病性大肠杆菌(UPEC)的 AMR 模式对于在全球范围内采取有效的公共卫生干预措施至关重要:本系统综述和荟萃分析旨在整合现有研究,提供有关埃塞俄比亚 AMR UPEC 的全面信息:方法:我们系统地搜索了 PubMed、Web of Science 和 Science Direct 等数据库,同时还包括谷歌学术(Google Scholar)上的文章。数据被提取到 Microsoft Excel 中,并使用 STATA 17.0 进行分析。计算科恩卡帕(Cohen's kappa)以评估审稿人的一致性,而 I2 统计量则评估异质性。进行了 Egger 检验以检测发表偏倚,并利用随机效应模型估算汇总的耐药性,对每种抗生素的 AMR 率分别进行汇总:UPEC的耐药率从阿米卡星的3.64%(95% CI:-4.38%至11.67%)到氨苄西林的85.32%(95% CI:78.6%至92.04%)不等。耐药率最高的是氨苄西林(85.32%),其次是阿莫西林 82.52%(95% CI:74.3%-90.74%)、四环素 60.67%(95% CI:51.53%-69.81%)和三甲双氨/磺胺甲噁唑 57.17%(95% CI:49.93%-64.42%)。相反,阿米卡星的耐药率较低,为 3.64%,美罗培南为 5.26%(95% CI:2.64%-7.88%)。UPEC的总MDR率为79.17%(95% CI:70.32%-88.01%),总ESBL产生率为29.16%(95% CI:22.36%-38.55%):在UPEC菌株中观察到了高水平的AMR,这突显了一个关键的公共卫生问题,需要通过强有力的抗菌药物管理和监测采取紧急行动,以保留有效的UTI治疗方案。
Antimicrobial resistance and ESBL production in uropathogenic Escherichia coli: a systematic review and meta-analysis in Ethiopia.
Background: Antimicrobial resistance (AMR) is a serious threat to global health systems. Escherichia coli is a major cause of urinary tract infections (UTIs). Understanding the AMR patterns of uropathogenic E. coli (UPEC) is crucial for effective public health interventions worldwide.
Objectives: This systematic review and meta-analysis aimed to consolidate existing research and provide a comprehensive information on AMR UPEC in Ethiopia.
Methods: We systematically searched databases such as PubMed, Web of Science, and Science Direct, along with including articles from Google Scholar. Data were extracted into Microsoft Excel and analysed using STATA 17.0. Cohen's kappa was computed to assess reviewer agreement, while the I2 statistic evaluated heterogeneity. Egger's tests were conducted to detect publication bias, and random-effects models were utilized to estimate the pooled resistance, with AMR rates for each antibiotic pooled separately.
Results: UPEC showed resistance rates, ranging from 3.64% (95% CI: -4.38% to 11.67%) for amikacin to 85.32% (95% CI: 78.6%-92.04%) for ampicillin. Highest resistance was to ampicillin (85.32%), followed by amoxicillin at 82.52% (95% CI: 74.3%-90.74%), tetracycline at 60.67% (95% CI: 51.53%-69.81%) and trimethoprim/sulfamethoxazole at 57.17% (95% CI: 49.93%-64.42%). Conversely, resistance rates were lower for amikacin at 3.64% and meropenem at 5.26% (95% CI: 2.64%-7.88%). UPEC demonstrated a pooled MDR rate of 79.17% (95% CI: 70.32%-88.01%) and a pooled ESBL production rate of 29.16% (95% CI: 22.36%-38.55%).
Conclusions: High levels of AMR were observed in UPEC strains, highlighting a critical public health issue requiring urgent action through robust antimicrobial stewardship and surveillance to preserve effective UTI treatment options.